<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1028">
  <stage>Registered</stage>
  <submitdate>9/01/2006</submitdate>
  <approvaldate>9/01/2006</approvaldate>
  <nctid>NCT00274508</nctid>
  <trial_identification>
    <studytitle>Effect of Tiotropium (Spiriva) on Exercise Tolerance in COPD Patients</studytitle>
    <scientifictitle>Effect of Tiotropium on Exercise Tolerance and Static and Dynamic Lung Volumes in COPD Patients (A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>205.223</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Pulmonary Disease, Chronic Obstructive</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Chronic obstructive pulmonary disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - tiotropium bromide

Treatment: drugs: tiotropium bromide


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Endurance time during a constant work rate exercise test to symptom limitation</outcome>
      <timepoint>2 hours and 15 minutes after trial medication administration on Day 42</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Constant work rate exercise test to symptom limitation</outcome>
      <timepoint>8 hours post-dose after 6 weeks of treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Breathing discomfort during constant work rate exercise test as measured by the modified Borg Scale</outcome>
      <timepoint>6 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Dynamic lung hyperinflation during exercise as determined by IRVdyn (IC minus VT) and EELVdyn (TLC)</outcome>
      <timepoint>6 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Evaluation of VE and VEcap during exercise (selected centers)</outcome>
      <timepoint>6 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Evaluation of static lung hyperinflation as measured by RV/TLC and by TGV(FRC)/TLC</outcome>
      <timepoint>6 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Evaluation of TAC (TAV = TLC(BOX)-VA(IG))</outcome>
      <timepoint>6 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Evaluation of slow vital capacity (SVC)</outcome>
      <timepoint>6 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Evaluation of maximal expiratory flow rates and volumes FEV1, FVC, FEF25-75%, FEF50%, FEF75%, SVC</outcome>
      <timepoint>6 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Evaluation of TGV, Raw, SGaw and RV</outcome>
      <timepoint>6 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Evaluation of SaO2, VO2, VCO2, Ti, Te, VE, VT, breathing frequency (f) during constant work rate exercise test</outcome>
      <timepoint>6 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Physician's Global Assessment</outcome>
      <timepoint>6 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Assessement of Pulse/heart rate and blood pressure in conjunction with spirometry and exercise</outcome>
      <timepoint>6 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in Physical examination and ECG</outcome>
      <timepoint>6 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Occurrence of Adverse Events</outcome>
      <timepoint>6 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria />
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2000</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>261</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,SA,VIC</recruitmentstate>
    <hospital>Phase I Unit - Randwick</hospital>
    <hospital>Immunology Department - Westmead</hospital>
    <hospital>Department of Respiratory Medicine - Daw Park</hospital>
    <hospital>The Queen Elizabeth Hospital - Woodville</hospital>
    <hospital>Department of Respiratory Medicine - Heidelberg</hospital>
    <postcode> - Randwick</postcode>
    <postcode> - Westmead</postcode>
    <postcode> - Daw Park</postcode>
    <postcode> - Woodville</postcode>
    <postcode> - Heidelberg</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Nova Scotia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Saskatchewan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hannover</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Kiel</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Köln</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Magdeburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>München</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Boehringer Ingelheim</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>To investigate whether tiotropium (Spiriva) improves exercise endurance in patients with COPD</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00274508</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Boehringer Ingelheim Study Coordinator</name>
      <address>Boehringer Ingelheim</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>